ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCBB: SNWV), today reported the publication of peer-reviewed, preclinical osteoarthritis research that demonstrates the ability of the Company’s Extracorporeal Shock Wave Technology (ESWT) to prevent the onset of osteoarthritis after a single treatment session that showed beneficial effects in as early as two weeks and continuing for at least three months.
